Compositions and methods for live, attenuated alphavirus formulations
Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.
1. A live attenuated alphavirus virus composition comprising:
one or more live, attenuated alphaviruses selected from the group consisting of chikungunya (CHIK) virus, o'nyong'nyong virus, Eastern equine encephalitis, Western equine encephalitis, and Venezuelan equine encephalitis;
10.0 to 20.0 mM HEPES buffer;
one or more carbohydrate agents having a concentration from 1.0% to 15% (w/v) selected from the group consisting of: trehalose, sucrose, mannitol, sorbitol, and galactose; and
0.1% to 1.0% (w/v) gelatin,
wherein the composition stabilizes live attenuated alphavirus compositions.
2. The virus composition of claim 1 , wherein the live, attenuated alphaviruses are Chikungunya (CHIK) viruses.
3. The virus composition of claim 1 , wherein the composition is in aqueous form.
4. The virus composition of claim 1 , wherein the composition is partially or wholly dehydrated.
5. The virus composition of claim 1 , wherein the composition comprises 10.0 to 20.0 mM HEPES, sucrose and gelatin.
6. The virus composition of claim 1 , wherein the gelatin concentration comprises 0.5% to 1.0% (w/v).
7. The virus composition of claim 1 , wherein the HEPES buffer concentration is 15 mM and the gelatin concentration is 0.5% to 1.0% (w/v).
8. The virus composition of claim 1 , further comprising 10 to 200 mM salt.
9. A method for decreasing inactivation of a live, attenuated alphavirus composition comprising, combining one or more live attenuated alphaviruses selected from the group consisting of chikungunya (CHIK) virus, o'nyong'nyong virus, Eastern equine encephalitis, Western equine encephalitis, and Venezuelan equine encephalitis with a composition comprising: 10 mM to 20 mM HEPES buffer; one or more carbohydrate agents at a concentration of 1.0% to 15% (w/v) selected from the group consisting of: trehalose, sucrose, mannitol, sorbitol, and galactose; and gelatin having a concentration of 0.1% to 1.0% (w/v), wherein the composition decreases inactivation of the live, attenuated alphavirus compositions.
10. The method of claim 9 , further comprising partially or wholly dehydrating the combination.
11. The method of claim 9 , further comprising partially or wholly re-hydrating the composition prior to administration.
12. The method of claim 9 , wherein the composition increases the shelf-life of an aqueous virus composition.
13. The method of claim 9 , wherein the concentration of HEPES buffer is 15 mM; and the gelatin concentration is 0.5% to 1.0% (w/v).
14. The method of claim 9 , wherein the live, attenuated alphavirus composition is formulated for use as a medicament for administration to a subject to reduce the onset of a health condition.
15. A kit for decreasing the inactivation of a live, attenuated alphavirus composition
comprising:
at least one container;
a composition comprising 10 mM to 20 mM HEPES buffer; one or more carbohydrate agents at a concentration of 1.0% to 15% (w/v) selected from the group consisting of: trehalose, sucrose, mannitol, sorbitol, and galactose;
0.1% to 1.0% (w/v) gelatin; and
an alphavirus, wherein the alphaviruses are selected from the group consisting of chikungunya (CHIK) virus, o'nyong'nyong virus, Eastern equine encephalitis, Western equine encephalitis, and Venezuelan equine encephalitis.